Equity Overview
Price & Market Data
Price: $6.50
Daily Change: +$0.07 / 1.08%
Daily Range: $6.50 - $6.50
Market Cap: $61,728,000
Daily Volume: 333
Performance Metrics
1 Week: 5.24%
1 Month: -11.80%
3 Months: -21.10%
6 Months: -51.84%
1 Year: -35.19%
YTD: -23.63%
Company Details
Employees: 102
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.